Adicet Bio (ACET)
(Delayed Data from NSDQ)
$1.48 USD
+0.04 (2.78%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $1.61 +0.13 (8.78%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Adicet Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 160 | 258 | 278 | 95 | 91 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 5 | 6 | 2 |
Total Current Assets | 162 | 261 | 282 | 100 | 93 |
Net Property & Equipment | 27 | 29 | 15 | 4 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 19 | 19 | 20 | 0 |
Deposits & Other Assets | 1 | 1 | 2 | 6 | 0 |
Total Assets | 207 | 331 | 339 | 154 | 94 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 3 | 2 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 13 | 7 | 6 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 5 | 14 | 0 |
Total Current Liabilities | 19 | 20 | 16 | 22 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 37 | 38 | 36 | 44 | 12 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 551 | 530 | 471 | 216 | 236 |
Retained Earnings | -381 | -238 | -168 | -106 | -154 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 170 | 292 | 303 | 110 | 82 |
Total Liabilities & Shareholder's Equity | 207 | 331 | 339 | 154 | 94 |
Total Common Equity | 170 | 292 | 303 | 110 | 82 |
Shares Outstanding | 70.10 | 42.80 | 31.90 | 19.60 | 5.20 |
Book Value Per Share | 2.43 | 6.83 | 9.50 | 5.60 | 15.71 |
Fiscal Year End for Adicet Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 224 | 248 | 160 | 183 | 205 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 3 | 3 | 3 |
Total Current Assets | 228 | 250 | 162 | 186 | 209 |
Net Property & Equipment | 24 | 25 | 27 | 28 | 30 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 19 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 269 | 293 | 207 | 233 | 278 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 3 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 12 | 13 | 13 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 18 | 17 | 19 | 20 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 34 | 34 | 37 | 39 | 39 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 674 | 668 | 551 | 546 | 540 |
Retained Earnings | -439 | -409 | -381 | -351 | -301 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 235 | 259 | 170 | 195 | 239 |
Total Liabilities & Shareholder's Equity | 269 | 293 | 207 | 233 | 278 |
Total Common Equity | 235 | 259 | 170 | 195 | 239 |
Shares Outstanding | 82.10 | 82.10 | 70.10 | 43.00 | 42.90 |
Book Value Per Share | 2.86 | 3.15 | 2.43 | 4.53 | 5.57 |